Important Disclaimer This article is for educational and informational purposes only. Semaglutide is a prescription medication approved in the United Kingdom for the treatment of type 2 diabetes (as Ozempic) and chronic weight management (as Wegovy). It should only be used under the supervision of a qualified healthcare professional. This content does not constitute medical advice. Individuals should not start, stop, or change any medication without consulting their doctor. Research peptides or compounded versions of semaglutide that are not approved medicines carry additional risks and are not recommended.
Note on Sources: This article is based on publicly available data from large-scale clinical trials, regulatory approvals, and published research as of July 2026.
What is Semaglutide?
Semaglutide is a synthetic peptide that mimics the action of glucagon-like peptide-1 (GLP-1), a hormone naturally produced in the gut. It works by stimulating insulin secretion, reducing glucagon release, slowing gastric emptying, and acting on areas of the brain that regulate appetite. These combined effects help lower blood sugar levels and reduce food intake.
It is administered as a once-weekly subcutaneous injection. Two formulations are currently approved in the UK: Ozempic for type 2 diabetes and Wegovy for weight management in adults with obesity or overweight with weight-related health conditions.
Key Clinical Research Findings
Semaglutide has been studied extensively in large clinical trial programmes. The SUSTAIN trials evaluated its use in people with type 2 diabetes, while the STEP trials focused on weight management.
In the STEP programme, participants using semaglutide 2.4 mg (Wegovy) alongside lifestyle interventions achieved an average weight loss of approximately 15% over 68 weeks. A meaningful proportion of participants lost 20% or more of their body weight. These results were significantly greater than those seen with placebo or lifestyle intervention alone.
In the SUSTAIN trials, semaglutide demonstrated improvements in blood sugar control (measured by HbA1c) and showed cardiovascular benefits. The SUSTAIN-6 trial, in particular, found a reduction in major adverse cardiovascular events in people with type 2 diabetes who had established cardiovascular disease or were at high risk.
These large-scale studies have provided a substantial body of evidence supporting semaglutide’s role in both diabetes management and weight loss.
Effectiveness in Weight Management and Diabetes
For weight management, semaglutide works primarily by reducing appetite and increasing feelings of fullness. Clinical data shows that when combined with diet and exercise, it can produce clinically meaningful weight loss for many people. However, weight regain is common after stopping treatment, suggesting that long-term use may be necessary to maintain results.
In type 2 diabetes, semaglutide helps lower blood glucose levels and has been shown to support cardiovascular risk reduction in certain patient groups. It is generally considered more effective than older GLP-1 receptor agonists, though individual responses can vary depending on factors such as starting weight, adherence to lifestyle changes, and duration of treatment.
Side Effects and Safety Profile
The most common side effects of semaglutide are gastrointestinal in nature. These include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These effects are often most noticeable when starting treatment or increasing the dose and tend to improve over time for many people.
More serious but less common risks include pancreatitis, gallbladder problems, and potential effects on heart rate. There have also been discussions around the risk of muscle loss during significant weight reduction, though this is not unique to semaglutide.
Because of these potential risks, semaglutide is not suitable for everyone. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Regular medical monitoring is recommended during treatment.
Comparison with Newer Agents
Newer medications such as tirzepatide (a dual GLP-1/GIP agonist) have shown greater average weight loss in clinical trials compared to semaglutide. Emerging data on retatrutide, a triple agonist, suggests even higher potential weight reduction in Phase 3 studies. However, semaglutide currently has a more established long-term safety and efficacy profile, with extensive real-world use and cardiovascular outcome data.
For many patients, semaglutide remains a valuable and well-proven treatment option, particularly where cardiovascular risk reduction is a priority or where newer agents are not suitable or available.
Current Status in the UK
Semaglutide is approved and regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. Ozempic is available for type 2 diabetes management, while Wegovy is approved for weight management. Access through the NHS is subject to specific criteria, and private prescriptions are also available.
As with all prescription medications, supply can sometimes be affected by demand, and patients are advised to follow guidance from their healthcare providers regarding availability and appropriate use.
Limitations of Current Research and Practical Considerations
While semaglutide has a strong evidence base, several limitations should be acknowledged. Most clinical trials have been conducted over periods of up to two years, so longer-term effects beyond this timeframe are still being studied. Additionally, significant weight loss is usually achieved alongside intensive lifestyle support, which may not always be replicated in everyday clinical practice.
Weight regain after discontinuation remains a challenge, highlighting that semaglutide is most effective as part of a long-term management strategy rather than a short-term solution. Individual responses can vary considerably, and not everyone achieves the average weight loss seen in trials.
Summary
Semaglutide is a well-established GLP-1 receptor agonist with substantial clinical evidence supporting its use in both type 2 diabetes and weight management. It offers meaningful benefits for many people but also carries potential side effects and requires medical supervision. While newer agents may offer greater weight loss in some cases, semaglutide continues to play an important role due to its proven track record and cardiovascular benefits.
As research continues and more real-world data becomes available, our understanding of how best to use this medication — and how it compares with newer treatments — will continue to evolve.You can explore research peptide options on PeptidesX.uk
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002. (STEP 1 Trial)
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375:1834-1844. (SUSTAIN-6 Trial)
- Medicines and Healthcare products Regulatory Agency (MHRA). Semaglutide (Ozempic and Wegovy) – UK regulatory information.
- ClinicalTrials.gov. Various STEP and SUSTAIN trial registrations.
Last Updated: July 2026